AzTrials
AzTrials

White Spot LesionNCT06178042

Effectiveness of MI Paste Plus and Remin Pro on Remineralization of Post-Orthodontic White Spot Lesions

A study testing MI Paste Plus and Remin Pro in people with White Spot Lesion and Remineralization, run by Izmir Katip Celebi University at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

One of the most undesired side effects of fixed orthodontic treatment is white spot lesions (WSLs), that appear on the buccal surface of teeth and cause aesthetic problems. The aim of this prospective study was to quantitively evaluate the remineralization effect of casein phosphopeptide-amorphous calcium… Read more about this study

Who is it for?
Ages 12 to 25 years
Conditions the study is for
White Spot Lesion, Remineralization
What is being tested?
MI Paste Plus and Remin Pro
Could I receive a placebo?
No, everyone receives an active treatment
How many people
39 participants
Where
1 siteTurkey (Türkiye)
Study dates
1 Feb 2020to 25 May 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 12 to 25 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • 12 to 25 years of age,
  • at least 12 months of orthodontic treatment with braces,
  • at least one upper anterior tooth with WSL.

Who cannot join

  • smoking,
  • enamel hypoplasia or fluorosis,
  • active periodontal disease,
  • dentin caries,
  • allergy to casein,
  • previous bleaching.

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Sevgi Göl Peynirci

    Konak, İzmir, 35220

Other trials in Turkey (Türkiye)

About this study

Official title: Evaluation of the Efficiency of Different Remineralization Methods Used In the Treatment of Post-Orthodontic White Spot Lesions With Quantitative Light-Induced Fluorescence Method

One of the most undesired side effects of fixed orthodontic treatment is white spot lesions (WSLs), that appear on the buccal surface of teeth and cause aesthetic problems. The aim of this prospective study was to quantitively evaluate the remineralization effect of casein phosphopeptide-amorphous calcium fluorophosphate (CPP-ACFP) containing (MI Paste Plus®) and hydroxyapatite, xylitol and fluoride containing (Remin Pro®) agents in remineralizing post orthodontics white spots using Quantitive Light-Induced Fluorescence Method (QLF) and ICDAS II criteria, compared to a control group in whom just a routine home care was instructed. Thirty-nine individuals who had recently completed orthodontic treatment, had at least one WSL on upper anterior teeth and aged between 12-25 years were included. The participants were randomly assigned into three groups of 13 each; (1) MI Paste Plus + routine home care; (2) Remin Pro + routine home care; and (3) routine home care (control). The treatment/ observation period was 12 weeks after bracket debonding. Fluorescence loss (∆F, %), lesion area (LA, mm2), lesion volume (∆Q, % × mm2), maximum fluorescence loss (∆Fmax), ICDAS II criteria of WSLs were measured at beginning (T0) and 4 (T1), 8 (T2), and 12 (T3) weeks later. Statistical significance was set at p<0.05.

Read the detailed description

This randomized controlled trial was a parallel arm 1-1 allocations. The study carried out in the Orthodontics Department, Izmir Katip Celebi University, Turkey. The protocol of the trial was approved by the Izmir Katip Celebi University Research Ethics Committee. A power analysis was carried out to provide that there was enough power to apply a statistical test of the research hypothesis to compare caries regression of Remin Pro to MI Paste Plus comparing with a control group in the remineralization of postorthodontic WSLs. Patients who finished their fixed appliance treatment in the clinic of the Department of Orthodontics, Faculty of Dentistry, Izmir Katip Celebi University who were found to comply with the study criteria were informed. Patients and parents who agreed to participate in the study signed an informed consent. A total of 39 people, 22 women and 17 men, aged between 14 and 23, were included in the study, with 13 people in each group. Gender distribution and average age of the groups are similar. Patients who are 12 to 25 years of age, at least had 12 months of orthodontic treatment with braces, at least had one upper anterior tooth with WSL included in the study. Patient who are smoking, with enamel hypoplasia or fluorosis, with active periodontal disease, with dentin caries, with allergy to casein, with previous bleaching excluded. Simple randomization was performed at the start of the study using a random number table prepared using SPSS software (version 26.0; New York, USA) for the allocation of patients who fulfilled all criteria and were willing to participate in this study. Group I: Patients were instructed to use MI Paste Plus (GC Europe, Leuven, Belgium) according to manufacturers instructions. Group II: Patients were instructed to use (Remin Pro, VOCO , Cuxhaven, Germany) a pea-sized amount of the cream. Group III. Patients (control group) used a 1450 ppm fluoridated tooth paste (Colgate Sensitive Pro-Relief, Colgate-Palmolive, Swidnica, Poland) for conventional tooth brushing and instructed to follow a routine home care. The patients were evaluated at baseline (T0) and every 30 days intervals for 3 months. The primary outcome measures were assessment of mineral loss based on fluorescence loss measurements using QLF. Lesions that scored 1 and 2 according to ICDAS II at debonding were included in the study. The buccal surfaces of the teeth were examined and evaluated by light induced fluorescence intraoral camera QLF-D Biluminator,™ (Inspektor-Pro, Amsterdam, Holland) for capturing fluorescent photographs in accordance with the manufacturer's instructions. Fluorescent images of the patient were evaluated in the 'White Spot Lesion' option of the analysis program (QA2.v.1.27). Following five QLF measurements were performed;

  1. Depth of lesion (∆F, %) shows the percentage of loss in fluorescence.
  2. Lesion area (LA, mm2) refers to the area covered by the demineralized area on the tooth.
  3. Lesion volume (∆Q, % × mm2) is derived from the combination of lesion area and lesion depth and represents the volume of the affected enamel.
  4. Maximum fluorescence loss (∆Fmax)is related to depth of lesion and mineral loss. Statistical analysis was performed with IBM® SPSS® (version 26. SPSS Inc., IBM Corporation, NewYork, USA). Descriptive statistics are expressed as number of units (n), percent (%), mean ± standard deviation (x ̅±ss), median (M), minimum (min), maximum (max), and interquartile range (IQR) values. The normal distribution of the data was evaluated with the Shapiro Wilk test of normality. Homogenicity of variances was evaluated with Levene's test.The concordance and differences in the first measurements and the second measurements were evaluated with the intra-class correlation coefficient and the paired samples t test. The ages of the groups were compared with one-way analysis of variance. The ΔF, lesion area and ΔFmax values of the groups in T0, T1, T2 and T3 were compared with two-way analysis of variance in repeated measurements. Bonferroni correction was applied in multiple comparisons. ΔQ, ICDAS II score, and difference values from baseline were compared between groups by Kruskal-Wallis analysis. In case of difference with Kruskal-Wallis analysis, Dunn-Bonferroni test was used for multiple comparisons. For ΔQ, ICDAS II score, Friedman analysis was performed for intragroup timepoint comparisons. Bonferroni correction was applied in multiple comparisons for Friedman analysis. Fisher Exact test was used to compare groups with categorical variables. If the chi-square test result was found to be significant, subgroup analyzes were performed with Bonferroni-corrected two-ratio z-test. Statistical significance level was set at p<0.05.
Being tested
MI Paste Plus, Remin Pro, Control
Keywords
White Spot Lesion, Remineralization, QLF, ICDAS II

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MI Paste PlusCombination product

    Briefly, a pea-sized amount of the cream was used once a day and was allowed to remain on the teeth for three minutes after conventional tooth brushing. Patient was advised to not to spit out the cream for 30 seconds to activate the product with saliva. Patient was advised to spit out the remaining amount to avoid swallowing excessive fluoride and to wait for 30 minutes after the treatment before rinsing or eating or drinking.

  • Remin ProCombination product

    The cream must remain on the teeth for at least three minutes once daily after conventional tooth brushing. Patient was advised to spit out the remaining amount to avoid swallowing excessive fluoride and to wait for 30 minutes after the treatment before rinsing or eating or drinking.

  • ControlCombination product

    Patients instructed to follow a routine home care.

Study groups in NCT06178042
Study groupRoleWhat they receive
MI Paste PlusExperimentalPatients were instructed to use MI Paste Plus (GC Europe, Leuven, Belgium) according to manufacturers instructions.
Receives: Combination Product: MI Paste Plus
Remin ProExperimentalPatients were instructed to use (Remin Pro, VOCO GmbH, Cuxhaven, Germany) a pea-sized amount of the cream.
Receives: Combination Product: Remin Pro
ControlActive comparatorPatients used a 1450 ppm fluoridated tooth paste (Colgate Sensitive Pro-Relief, Colgate-Palmolive, Swidnica, Poland) for conventional tooth brushing.
Receives: Combination Product: Control

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mineral Content Assessment (ΔF / Depth of lesion)

    The buccal surfaces of the teeth were examined and evaluated by light induced fluorescence intraoral camera QLF-D Biluminator,™ (Inspektor-Pro, Amsterdam, Holland) for capturing fluorescent photographs in accordance with the manufacturer's instructions.

    Measured: The patients were evaluated at baseline (T0) and every 30 days intervals for 3 months.

  2. Mineral Content Assessment (LA / Lesion area)

    The buccal surfaces of the teeth were examined and evaluated by light induced fluorescence intraoral camera QLF-D Biluminator,™ (Inspektor-Pro, Amsterdam, Holland) for capturing fluorescent photographs in accordance with the manufacturer's instructions.

    Measured: The patients were evaluated at baseline (T0) and every 30 days intervals for 3 months.

  3. Mineral Content Assessment (∆Q / Lesion volume)

    The buccal surfaces of the teeth were examined and evaluated by light induced fluorescence intraoral camera QLF-D Biluminator,™ (Inspektor-Pro, Amsterdam, Holland) for capturing fluorescent photographs in accordance with the manufacturer's instructions.

    Measured: The patients were evaluated at baseline (T0) and every 30 days intervals for 3 months.

  4. Mineral Content Assessment (∆Fmax / Maximum fluorescence loss)

    The buccal surfaces of the teeth were examined and evaluated by light induced fluorescence intraoral camera QLF-D Biluminator,™ (Inspektor-Pro, Amsterdam, Holland) for capturing fluorescent photographs in accordance with the manufacturer's instructions.

    Measured: The patients were evaluated at baseline (T0) and every 30 days intervals for 3 months.

Secondary outcomes (1)
  1. Visual Caries Regression Assessment

    ICDAS II scoring

    Measured: The patients were evaluated at baseline (T0) and every 30 days intervals for 3 months.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Dec 2023
  2. Study start1 Feb 2020
  3. Primary completion1 Feb 2022
  4. Study completion25 May 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Thirty-nine patients were randomized in a 1:1:1 ratio to either MI Paste Plus or Remin Pro or control group.
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
39 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06178042
Sponsor's protocol ID
SPEYNIRCI
Status last verified
Dec 2023
First submitted
18 Sep 2023
Last updated
20 Dec 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing MI Paste Plus and Remin Pro in people with White Spot Lesion and Remineralization, run by Izmir Katip Celebi University at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 Dec 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mineral Content Assessment (ΔF / Depth of lesion) (time frame: The patients were evaluated at baseline (T0) and every 30 days intervals for 3 months.). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Dec 2023; AzTrials last refreshed its copy on 6 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in